OncoSec to Present at Scientific and Investment Conferences in March

SAN DIEGO, March 7, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present preclinical data from studies involving in vivo intratumoral IL-12 treatment in mouse cancer models. The data will be presented in a poster at an upcoming Keystone Symposia conference. In addition, Punit Dhillon, OncoSec President and CEO, will present a corporate overview at two investment conferences this month, including:  Maxim Group's Inaugural Healthcare Investor & Partnering Conference and the 2017 BIO Asia International Conference. 

Keystone Symposia Conference: Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology  OncoSec will present a poster at the Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology conference to be held on March 19-23, 2017, in Whistler, British Columbia, Canada. Details of the presentation are as follows:

Further details on this Keystone Symposia poster presentation will be provided in upcoming Company communications. For more information about this conference, please visit: http://keystonesymposia.org. 

Maxim Group's Inaugural Healthcare Investor & Partnering Conference  Mr. Dhillon will present a corporate overview at Maxim Group's Biotech Investor & Partnering Conference on March 7, 2017 at 11:20 AM China Standard Time at The Park Hyatt Shanghai in Shanghai, China. In addition, he will participate in a panel discussion entitled: "Innovations in Oncology – From Chemo to Immunotherapy" on the same day at 10:00 AM local time. For more information about this conference, please visit: http://www.maximgrp.com. 

BIO Asia International Conference  Mr. Dhillon will present a corporate overview at the BIO Asia International Conference on March 14, 2017 at 11:15 AM Japanese Standard Time at the Grand Hyatt Tokyo in Tokyo, Japan. For more information about this conference, please visit: https://www.bio.org/events/bio-asia-internationalconference.

About OncoSec Medical Incorporated OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer. ImmunoPulse® is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors as well as a systemic immune response. OncoSec's lead program, ImmunoPulse® IL-12, is currently in clinical development for metastatic melanoma and triple-negative breast cancer. The program's current focus is on the significant unmet medical need in patients with melanoma who are refractory or non-responsive to anti-PD-1/PD-L1 therapies. In addition to ImmunoPulse® IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse® platform. For more information, please visit www.oncosec.com.

CONTACTS:

Investor Relations: OncoSec Medical Incorporated 855-662-6732 [email protected]

Media: Laura Radocaj DGI Comm 212-825-3210 [email protected]

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oncosec-to-present-at-scientific-and-investment-conferences-in-march-300419332.html

SOURCE OncoSec Medical Incorporated